92 related articles for article (PubMed ID: 3674760)
21. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
25. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone for advanced breast cancer.
Gupta P; Tandon R
J Assoc Physicians India; 1992 Apr; 40(4):282. PubMed ID: 1452548
[No Abstract] [Full Text] [Related]
27. Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
Bezwoda WR; Hesdorffer CS; Dansey RD
S Afr Med J; 1987 Oct; 72(7):465-7. PubMed ID: 3660150
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
Leonardi V; Meli M; Palmeri S; Russo A; Rini GB; Peralta S; Rausa L
J Chemother; 1995 Apr; 7(2):160-6. PubMed ID: 7545224
[TBL] [Abstract][Full Text] [Related]
29. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer.
Fountzilas G; Afthonidis D; Geleris P; Salem N; Kottas G; Halkidis C; Apostolidis P; Beer M; Tourkantonis A
Anticancer Res; 1992; 12(1):231-4. PubMed ID: 1567171
[TBL] [Abstract][Full Text] [Related]
30. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
[TBL] [Abstract][Full Text] [Related]
31. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine.
Green JA; Slater AJ; Campbell IR; Kelly V
Breast Cancer Res Treat; 1996; 39(2):155-63. PubMed ID: 8872324
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
[TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital.
Tepmongkol P; Suphaphongs N; Thansakul A; Jirapanuwat S; Skulchan V; Rojananin S; Chantarakul N
J Med Assoc Thai; 1989 Feb; 72(2):82-9. PubMed ID: 2738491
[TBL] [Abstract][Full Text] [Related]
34. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
Bezwoda WR; Dansey R; Seymour L
Oncology; 1989; 46(4):208-11. PubMed ID: 2740063
[TBL] [Abstract][Full Text] [Related]
35. Neurotoxicity and efficacy of combined vinca alkaloids in breast cancer.
Stewart DJ; Maroun JA; Lefebvre B; Heringer R
Cancer Treat Rep; 1986 May; 70(5):571-3. PubMed ID: 3011256
[TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
Holmes FA; Yap HY; Esparza L; Buzdar AU; Blumenschein GR; Hug V; Hortobagyi GN
Cancer; 1987 Jun; 59(12):1992-9. PubMed ID: 3567861
[TBL] [Abstract][Full Text] [Related]
37. Further study of five-drug combined chemotherapy for advanced breast cancer.
Liu GS; Li GC
Chin Med J (Engl); 1986 Sep; 99(9):757-9. PubMed ID: 3100238
[No Abstract] [Full Text] [Related]
38. [Polychemotherapy of advanced cancer of the breast].
Mascia V; Massidda B; Pellegrini A
Minerva Med; 1978 May; 69(26):1803-8. PubMed ID: 662182
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
[TBL] [Abstract][Full Text] [Related]
40. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
Ransom DT; Neuberg D; Loprinzi CL; Tormey DC; Blum RH; Harris JE; Asbury RF; Falkson G
Am J Clin Oncol; 1991 Feb; 14(1):45-8. PubMed ID: 1898999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
